Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Halozyme Therapeutics Inc (NASDAQ:HALO)

11.53
Delayed Data
As of Dec 09
 -0.10 / -0.86%
Today’s Change
6.96
Today|||52-Week Range
17.78
-33.47%
Year-to-Date

Five Year Financial Summary

Total Revenue

Cash & Short Term Investments

Cash From Operations

All Currency in US Dollars4 Quarter
Trend
Quarter 4
2015
Quarter 1
2016
Quarter 2
2016
Quarter 3
2016
Revenue and IncomeNet Revenues52.2M42.5M33.3M31.9M
 
 
 
 
 
Cost of Goods Sold8.0M7.3M7.7M8.5M
 
 
 
 
 
Depreciation And Amortization459.0K489.0K623.0K654.0K
 
 
 
 
 
 
Operating ExpensesGross Income43.8M34.7M25.0M22.7M
 
 
 
 
 
General Expenses38.3M50.9M46.8M45.5M
 
 
 
 
 
Research And Development27.7M40.1M35.5M33.9M
 
 
 
 
 
Total Operating Expenses46.8M58.7M55.1M54.6M
 
 
 
 
 
 
Non-Operating ExpensesOperating Income5.5M-16.2M-21.7M-22.7M
 
 
 
 
 
Interest Expense On Debt1.3M3.9M5.2M5.3M
 
 
 
 
 
 
Income Taxes, Minority Interest and Extra ItemsPre-Tax Income4.3M-19.8M-26.6M-27.7M
 
 
 
 
 
Income Taxes0.000.00-300.0K-1.3M
 
 
 
Net Income4.3M-19.8M-26.9M-28.9M
 
 
 
 
 
 
Shares To Calculate EPSShares To Calculate EPS127.2M127.6M128.0M128.2M
 
 
 
 
 
Shares To Calculate EPS Diluted129.2M127.6M128.0M128.2M
 
 
 
 
 
 
Earnings Per ShareEPS$0.03-$0.16-$0.21-$0.23
 
 
 
 
 
EPS Diluted$0.03-$0.16-$0.21-$0.23